Why are these four pharma stocks drawing investors’ attention?

Be the First to Comment Read

Why are these four pharma stocks drawing investors’ attention?

Follow us on Google News:
 Why are these four pharma stocks drawing investors’ attention?
Image source: Josep Suria,Shutterstock


  • CRISPR Therapeutics (NASDAQ: CRSP) released its quarterly earnings on July 29. The stock was trading at US$119.96, up 0.81% at 2:14 pm ET.
  • Cocrystal Pharma’s (NASDAQ: COCP) new drug showed effective results against covid. The stock recently became a part of the Russell Microcap® Index. 
  • Erytech Pharma (NASDAQ: ERYP) trading volume jumped to 52,976,262 today after FDA granted eryaspase Fast Track designation.

Pharmaceuticals stocks engaged in the manufacturing of covid-related drugs saw significant gains over the past months. Some of these stocks saw huge investor interests on Friday.

Although the benchmark US indices declined in Friday’s session, four pharmaceutical stocks saw significant traction, indicating investors’ attention on the shares of these companies.

We explore here the stocks to understand what they do and how they have performed, which may have raised investors’ attention.

CRISPR Therapeutics AG (NASDAQ: CRSP) has a market capitalization of US$10 billion and a P/E ratio of 24.14, with a forward P/E for one year of 180.30.

This gene-editing company focuses on the development of CRISPR/Cas9-based therapeutics. 

Also Read: Riding the construction wave: 10 fastest growing infra stocks

It released its quarterly earnings on July 29 after market hours. The average volume has increased to 1,275,527 on its strong quarterly results.

The revenue for Q2 of 2021 was US$ 900.2 million compared to US$ 40,000 for the same duration in 2020. Net income was US$ US$ 759 million or EPS diluted per common share US$ 19.44, compared to a net loss of US$ 79.7 million or net loss diluted per share of US$ 1.30 in the prior-year quarter. 

CRSP has received Orphan Drug Designation (ODD) from FDA for CTX130 for T-cell lymphoma treatment. Its phase 1 clinical trials data is expected this year.

The stock is trading at US$ 122.89 at 11:38 am ET today. 

Also Read: Which are the popular food and beverage stocks on Wall Street?

Source: Pixabay

Also Read: Banking on Banks: Five hot bank stocks based on earnings to explore

Cocrystal Pharma, Inc. (NASDAQ: COCP) market capitalization is US$114 million. Cocrystal is a clinical-stage biotechnology company. It is engaged in discovering and developing novel antiviral therapeutics.

On June 28, the company became part of the Russell Microcap® Index.

On July 29, Cocrystal announced that its SARS-CoV-2 3CL protease inhibitor CDI-45205 and several analogs showed effective in vitro activity against Delta and Gamma variants of SARS-CoV-2.

In the March quarter, 2021, the company did not have any revenue, and the net loss was US$2.7 million compared to a net loss of US$2.0 million in the same quarter the previous year. Net loss per share diluted was US$ 0.04 against US$ 0.05 in a year-ago period.

It is trading at US$ 1.15, down 4.15% at 12:56 pm ET, today with a share volume of 13,285,576.

Also Read: Five fastest-growing S&P 500 stocks making investors drool

Erytech Pharma S.A. (NASDAQ: ERYP) is a clinical-stage biopharmaceutical company. It is engaged in developing innovative red blood cell-based therapeutics therapies for cancer and orphan diseases.

This has US$ 156 million in market capitalization.

The stock jump could be because of the company’s announcement of FDA Fast Track designation. The FDA granted eryaspase Fast Track designation to treat acute lymphocytic leukaemia patients (ALL) who have hypersensitivity reactions to E. coli-derived (PEG-ASNase).

Its revenue for FY 2020 ended on December 31, was US$ 4.55 million, and net loss was US$ 89.69 million against revenue of US$ 5.9 million and a net loss of US$ 70 million in FY 2019.

The share volume is 52,976,262. It is trading 48.66% up from the previous close at US$ 6.11 at 1:23 pm ET today.

Also Read: Making a Splash: Six advertising stocks that are hard to miss

Allied Healthcare Products, Inc. (NASDAQ: AHPI) manufactures respiratory products for hospital and health care centers, including sub-acute care facilities, home health care, and emergency medical care.

It is a small company with a US$ 35.8 million market capitalization. 

The stock saw a massive rise in trading share volume today to be 79,313,020 without any known reason. Its average share volume is 6,264,063.

Its net sales for March quarter 2021 was US$ 7.97 million, a 1.6% decline YOY. It incurred a net loss of US$ 413 million against US$ 330 in the previous year March quarter. The net loss diluted was US$ 0.10 compared to US$ 0.08 in a year-ago period.  

The stock jumped 55.13% today to US$ 9.215 at 1:50 pm ET. 

Please note: The above constitutes a preliminary view, and any interest in stocks/cryptocurrencies should be evaluated further from an investment point of view.


Featured Articles